Charles River Takes Center Stage at Neuroscience 2024
Charles River Laboratories International, Inc. (NYSE: CRL) is set to share its wealth of knowledge and the latest innovations in neuroscience at the highly anticipated Neuroscience 2024 annual meeting of the Society for Neuroscience (SfN). The event promises to unite some of the brightest minds in neuroscience, where Charles River will be showcasing a total of 18 scientific posters, developed by both their team and in collaboration with clients.
A Commitment to Advancing Neuroscience
At the forefront of this year’s meeting, Charles River reaffirms its commitment to transforming neuroscience research. Antti Nurmi, Ph.D., MSc, the General Manager of CNS Pharmacology at Charles River, emphasizes the organization’s mission to provide translational expertise that enhances preclinical models and innovative drug discovery processes. By doing so, they aim to improve patient outcomes worldwide.
Significant Contributions to Drug Discovery
Advancements in genetics, pathology, biomarkers, and endpoints are pivotal in fostering progress within neuroscience drug discovery. During the conference, Charles River’s experts will not only present posters but also engage in discussions concerning recent breakthroughs and their applications in treating neurodegenerative conditions. Some of the noteworthy presentations include:
- Establishment and validation of an in vitro co-culture model to study myelination using human iPSC-derived glutamatergic neurons and oligodendrocytes presented by Malika Bsibsi.
- An iPSC-derived neuroinflammation in vitro model of neurons and glial cells also presented by Malika Bsibsi.
Driving Discussion Around ALS Research
On the morning of a key conference day, Charles River's scientific experts will hold an essential discussion regarding the latest findings and their implications for ALS research. The session, scheduled for Monday, will see notable scientists such as Susanne Back, Ph.D., and Philip Mitchell, Ph.D., as they explore how cellular and animal models can reflect the complexities of disease pathology.
Collaborative Efforts and Recent Announcements
Charles River's dedicated team of nearly 200 neuroscientists spans drug discovery and development, providing comprehensive support from foundational research through to regulatory stages. Since 2018, their contributions have supported 80% of newly approved neuroscience medications by the United States Food & Drug Administration (FDA).
Recent Innovations Making Waves
Among their latest strides, Charles River is proud to highlight a strategic collaboration with CEBINA that aims to propel groundbreaking neuroscience research. Additionally, through their latest integration of Insightec’s low-frequency ultrasound technology, precise therapeutic delivery methods are being established, which can reach deeply seated brain structures. Utilizing their AI-powered solution, Logica®, they are transforming drug discovery processes to accelerate critical brain disease research alongside partners like H. Lundbeck A/S.
Engage with Charles River at Neuroscience 2024
A detailed schedule of Charles River's contributions and activities throughout Neuroscience 2024 can be found online for those interested in their vast array of offerings. Their team will also be available at Booth #417, welcoming professionals eager to discuss neuroscience research, drug discovery innovations, and potential collaborations.
Frequently Asked Questions
What is the main focus of Charles River at Neuroscience 2024?
Charles River will present 18 scientific posters and lead discussions on advancements in neuroscience drug discovery and neurodegenerative disease research.
Who are the key speakers from Charles River at the event?
Notable speakers will include Antti Nurmi, Susanne Back, Ph.D., and Philip Mitchell, Ph.D., who will share their insights during presentations and discussions.
How does Charles River contribute to drug discovery?
Charles River supports drug discovery by offering comprehensive services and collaborating on research, which has led to significant contributions, particularly in neuroscience.
What recent collaborations has Charles River engaged in?
Recently, they announced a strategic collaboration with CEBINA and integrated Insightec’s ultrasound technology to enhance drug delivery methods.
Where can I find more information about Charles River's activities at the conference?
Details regarding Charles River's schedule and activities can be accessed online, providing insights into their presentations and participation at Neuroscience 2024.
